STOCK TITAN

Talphera to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026

Talphera (Nasdaq: TLPH) will discuss third-quarter 2026 financial results and recent business progress on a conference call on November 12, 2026.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
earnings date

Talphera (Nasdaq: TLPH) will discuss third-quarter 2026 financial results and recent business progress on a conference call on November 12, 2026. The call and webcast begin at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time and cover the quarter ended September 30, 2026. A webcast replay will remain available on the company website for 90 days after the event.

Loading...
Loading translation...

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SAN MATEO, Calif., Nov. 4, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss financial results for the third quarter ended September 30, 2026 and recent business progress.

Conference Call and Webcast Information

  • Date: Thursday, November 12, 2026 at 4:30 PM ET/1:30 PM PT
  • Participant Dial-in (North America): 1-800-836-8184
  • Participant Dial-in (International): 1-646-357-8785
  • Conference ID: 69368
  • Webcast Access: Click here 

The event can also be accessed in the Upcoming Events page in the Investors section of the Talphera website at www.talphera.com.

A replay of the webcast will be available on the Talphera website for 90 days after the event.

About Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad® is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Nafamostat has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).

This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

Talphera Logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-report-third-quarter-2026-financial-results-on-thursday-november-12-2026-302928338.html

SOURCE Talphera, Inc.

Keep reading